

From: [James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)  
 To: [James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)  
 CC: [James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)  
 Subject: [James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)  
 Date: [James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)

Notes attached please find the 30 Day pricing for Novartis. **Please confirm that you have reviewed this email.**

Product Name	NDC	DRUG_FREQ_DESC	INTRODUCED_TO_MARKET_DATE	WAC_AT_INTRODUCTION	MARKETING_FREQ_FLAN	MARKETING_FREQ_NONPUBLIC	ESTIMATED PATIENTS [The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed.]	BREAKTHROUGH_THERAPY_INDICATOR	PRIORITY_REVIEW_INDICATOR	ACQUISITION_DATE	ACQUISITION_PRICE	ACQUISITION_PRICE_NONPUBLIC	ACQUISITION_PRICE_COMMENT	GENERAL COMMENTS
BEVOUR (Enzalutamide)	0076-0872-01	BEVOUR (Enzalutamide) is a novel androgen receptor (AR) inhibitor for the treatment of Prostate Cancer (PC). BEVOUR is administered by injection and is available in 100mg and 200mg strengths. BEVOUR injection is a sterile, preservative-free, clear to light yellowish colorless to slightly turbid solution in a single-dose unit for intravenous administration. Each mL is designed to contain 100 mg of enzalutamide (100 mg/1 mL) and 0.9% sodium chloride (0.9% NaCl) solution for injection. USP <a href="#">Controlled Substances</a> 2.2.	10/2019	\$1,800		N/A	Novartis considered many factors in determining the price of BEVOUR. This value reflects a value that is substantially below the burden of PC. BEVOUR (100 mg) is a novel androgen receptor (AR) inhibitor for the treatment of Prostate Cancer (PC). BEVOUR is administered by injection and is available in 100mg and 200mg strengths. BEVOUR injection is a sterile, preservative-free, clear to light yellowish colorless to slightly turbid solution in a single-dose unit for intravenous administration. Each mL is designed to contain 100 mg of enzalutamide (100 mg/1 mL) and 0.9% sodium chloride (0.9% NaCl) solution for injection. USP <a href="#">Controlled Substances</a> 2.2.	No	Yes	N/A	N/A	N/A	N/A	There are 700,000 patients with mCRPC in the US for whom BEVOUR may be prescribed. However, it is only available to 50,000 US patients who are enrolled in the BEVOUR study. BEVOUR is a novel androgen receptor (AR) inhibitor for the treatment of Prostate Cancer (PC). BEVOUR is administered by injection and is available in 100mg and 200mg strengths. BEVOUR injection is a sterile, preservative-free, clear to light yellowish colorless to slightly turbid solution in a single-dose unit for intravenous administration. Each mL is designed to contain 100 mg of enzalutamide (100 mg/1 mL) and 0.9% sodium chloride (0.9% NaCl) solution for injection. USP <a href="#">Controlled Substances</a> 2.2.

James Mcvey  
 Associate Director, Government Pricing  
 Phone: +1 862 288 4456  
[James.Mcvey@Novartis.com](mailto:James.Mcvey@Novartis.com)  
 Managed Markets Finance/CA  
 Novartis Pharmaceuticals  
 One Health Plaza  
 East Hanover, NJ 07930-1000  
 USA